Author’s Reply by Sajjadi, Hamid & Poorsalman, Hossein
Letter
Author’s Reply
Hamid Sajjadi1,2, MD, FACS; Hossein Poorsalman3, MD
1San Jose Eye and Laser Medical Center, Cupertino, California, USA
2Department of Ophthalmology, Acacia Medical Center. Dubai, UAE
3Department of Ophthalmology, Red Crescent Hospital, Dubai, UAE
ORCID:
Hamid Sajjadi: https://orcid.org/0000-0002-7897-2091
J Ophthalmic Vis Res 2019; 14 (4): 534–535
Sir,
Thank you for your interest in our article.[1] You
raised some questions about our case report;
below please notice our answers:
1. As we mentioned in our article the mitochon-
drial mutation for Leber hereditary optic neuropa-
thy (LHON) was not present in this case and the
patient had been labeled as LHON by previous
clinicians. Therefore, the diagnosis of LHON was
completely presumptive.
The ICP that was measured in our case was 18
cmH2O in lateral decubitus position which used
to be high before 2016; however, it has been
challenged in recent articles that in children it can
be up to 26 cmH2O. However, these articles also
state that in children you have to interpret the ICP
measurement in the context of clinical signs and
symptoms, there in effect an lumbar puncture (LP)
is not reliable in children. Our patient had some
MRI signs of pseudotumor cerebri (PTC) includ-
ing extensive fluid around the optic nerve and
hygroma. Hygromas are normal in older than 60
years olds but not in a child. There are also ample
reports of low tension PTCs in the literature.[2, 3]
Normal IOP does not exclude PTC and what makes
our report unique is the dramatic response of vision
and stereopsis to the ICP lowering treatment.
2. As optic atrophy is an ultimate sign of every
optic neuropathy, finding a way in elucidating
the definite cause of it is really important. There
are lots of cases of optic atrophy with unknown
cause and there should be a way to explain their
origin. Our previous article was an effort to open
this discussion and was based on many neuro-
ophthalmology cases that we have seen in these
years. Our diagnosis was not merely based on
the optic nerve head (ONH) feature of our patient,
but was also dependent on the MRI findings and
the dramatic response to acetazolamide therapy.
As explained, we have reported 164 cases of LP
proven PTC without visible papilledema.[3] Many of
these cases presented with optic atrophy and no
papilledema but did have high ICP on LP.
3. We think our pictures have the best possible
quality with Topcon OCT device and no other
machine would produce a better ganglion cell
layer (GCL) analysis. The first picture was taken
by a Topcon 2000 machine and the later ones
were done at different center by the most recent
software; therefore, they look different. However,
the presence of central scotoma is obvious in the
original GCL analysis which opened up as the
patient’s central vision improved. In his last visit (4
months ago), his BCVA was 20/20 in each eye.
4. It is mentioned in our article that the mito-
chondrial mutation for LHONwas not present in this
patient. There were neither 14484 nor any other
mutations in our case. Therefore, the theory of
visual recovery secondary to this mutation cannot
be correct.
5. Although spontaneous stopping of damage
has been reported in LHON, an improvement from
20/200 to 20/20 has never been reported.
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